Huakang Biomedical Holdings

8622

The current Huakang Biomedical Holdings (8622) market capitalization is approximately HK$217.71M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Huakang Biomedical Holdings's market cap fluctuates with changes in its share price and share count. Last updated: December 31, 2025 at 11:57 PM Eastern Time

In the most recently reported quarter, Huakang Biomedical Holdings (8622) generated HK$6.75M in revenue, representing a +5.50% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: January 1, 2026 at 3:10 AM Eastern Time

In the most recently reported fiscal year, Huakang Biomedical Holdings (8622) generated net income of HK$-4.42M, compared with HK$-6.37M in the prior fiscal year, representing a +30.54% year over year change. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: January 1, 2026 at 3:10 AM Eastern Time

According to its latest quarterly filing, Huakang Biomedical Holdings (8622) reported EBITDA of HK$-0.90M, representing a -20.15% year over year change. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: January 1, 2026 at 3:10 AM Eastern Time

As of the most recent reporting period, the company's debt-to-equity ratio stands at 0.08x, calculated as total debt divided by total shareholders' equity. A lower debt-to-equity ratio generally indicates a more conservative capital structure with less reliance on external borrowing, while a higher ratio suggests greater financial leverage and potentially higher sensitivity to interest rates, refinancing conditions, and earnings volatility. The debt-to-equity ratio should be interpreted in the context of the company's industry, business model, cash flow stability, and balance sheet composition. Last updated: January 1, 2026 at 3:10 AM Eastern Time

Based on the latest available data, Huakang Biomedical Holdings (8622) is currently trading at a last twelve months (LTM) P/E ratio of -42.27x. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: January 1, 2026 at 3:10 AM Eastern Time

In the most recently reported quarter, Huakang Biomedical Holdings (8622) revenue was HK$6.75M. Earnings per share (EPS) for the quarter were HK$-0.00. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: January 1, 2026 at 3:10 AM Eastern Time

Huakang Biomedical Holdings (8622) does not currently pay a dividend. Over the last twelve months (LTM), the company paid HK$0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: January 1, 2026 at 3:10 AM Eastern Time

Based on the latest available analyst coverage, Huakang Biomedical Holdings (8622) currently carries a not available consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: January 1, 2026 at 3:10 AM Eastern Time

Like other publicly traded stocks, Huakang Biomedical Holdings (8622) shares are bought and sold on stock exchanges such as SEHK and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Huakang Biomedical Holdings (8622) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add 8622 to your watchlist.

Huakang Biomedical Holdings trades under the ticker symbol 8622 on the SEHK stock exchange. The ticker 8622 is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, Huakang Biomedical Holdings (8622) employs approximately 98 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: December 31, 2025 at 11:57 PM Eastern Time